Table 1.
Active CED Trials for Adult Patients With Glioma
| Study | Trial Number | Phase | Status |
|---|---|---|---|
| D2C7 for recurrent malignant glioma | NCT02303678 | 1/2 | Recruiting |
| D2C7-IT with atezolizumab for recurrent gliomas | NCT04160494 | 1 | Recruiting |
| PVSRIPO for recurrent GBM | NCT01491893 | 2 | Active |
| PVSRIPO and pembrolizumab in patients with recurrent glioblastoma (LUMINOS-101) | NCT04479241 | 2 | Recruiting |
| MDNA55 in recurrent or progressive GBM | NCT02858895 | 2 | Completed, awaiting results |
| EGFRvIII CAR T cells for recurrent GBM (INTERCEPT) | NCT03283631 | 1 | Suspended, awaiting protocol amendment |
| 186Rhenium nanoliposomes (186RNL) in recurrent glioma | NCT01906385 | 1/2 | Recruiting |
| Topotecan via CED for recurrent grade III/IV glioma | NCT03927274 | 1 | Recruiting |
| Recombinant bone morphogenetic protein 4 administered via CED in progressive or multiple recurrent GBM | NCT02869243 | 1 | Active |
| Nanoliposomal irinotecan for recurrent high-grade glioma | NCT02022644 | 1 | Active |
| Convection-enhanced delivery of OS2966 for patients with high-grade glioma undergoing a surgical resection | NCT04608812 | 1 | Recruiting |
Abbreviations: CAR T, chimeric antigen receptor T; CED, convection-enhanced delivery; GBM, glioblastoma.